Rabbi who recovered from COVID donates plasma in experimental treatment
Rabbi Daniel Nevins donating blood plasma at Mount Sinai Hospital in New York, May 27, 2020. Image by Courtesy of Daniel Nevins via JTA
(JTA) — Among the mysteries of the coronavirus is that some patients suffer and ultimately die from the disease while others experience the symptoms as akin to a mild cold.
Rabbi Daniel Nevins is in the latter category. The dean of the rabbinical school at the Jewish Theological Seminary, Nevins was laid up for a few days earlier this month with a fever and some aches, and then recovered.
Nevins was tested for the coronavirus on March 12 and a week later got back a positive result. A week after that, he was tested again. Friday morning, he got the result: All clear.
Within hours, Nevins was hooked up to a machine at Mount Sinai Hospital in New York to donate blood plasma. In the race to develop effective treatments for the disease, researchers are investigating whether antibodies from the blood of people who have successfully fought off the disease may provide treatment for people who with more serious symptoms.
As a public service during this pandemic, the Forward is providing free, unlimited access to all coronavirus articles. If you’d like to support our independent Jewish journalism, click here.
Earlier this week, the Food and Drug Administration allowed doctors to treat critically ill coronavirus patients with plasma on an experimental basis. Plasma has been shown effective in treating other infectious diseases, like polio, measles and influenza.
“I felt fortunate that my mild case of this illness might turn into a blessing for people who are seriously ill,” Nevins told the Jewish Telegraphic Agency. “The Torah teaches us not to stand idly by the blood of our neighbor. My Midrash [interpretation] is that no, instead lie down in a donor bed and give plasma.”
Mount Sinai was among the first hospitals in the country to figure out how to detect antibodies in the blood of people who had recovered from coronavirus, the New York Times reported. Whether or not those antibodies are effective remains to be seen.
“It’s kind of difficult scientifically to know how valuable it is in any disease until you try,” said David Reich, the president and chief operating officer of Mount Sinai, told the Times. “It’s not exactly a shot in the dark, but it’s not tried and true.”
The post Rabbinical school dean participates in experimental coronavirus treatment appeared first on Jewish Telegraphic Agency.
A message from our Publisher & CEO Rachel Fishman Feddersen
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.
We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.
If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.
— Rachel Fishman Feddersen, Publisher and CEO
